Merck Sharp & Dohme Llc

This trial is testing whether an experimental biologic called MK-6194 can reduce disease activity in adults with systemic lupus erythematosus (SLE), an autoimmune condition that causes inflammation and organ damage. Participants receive either MK-6194 or a placebo as an injection…

This study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with certain blood cancers like Hodgkin lymphoma and B-cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study also looked at each drug alone in so…

This study tested an experimental drug called MK-6194 in adults with non-segmental vitiligo, a condition that causes white patches on the skin. The goal was to see if the drug could safely reduce the amount of vitiligo on the face compared to a placebo. The trial was stopped earl…

This study tested a personalized mRNA vaccine (mRNA-4157) combined with the immunotherapy drug pembrolizumab for people with advanced but removable skin cancer (cutaneous squamous cell carcinoma). The goal was to see if the combination could prevent the cancer from coming back be…

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to precise, high-dose radiation (SBRT) could help prevent early-stage non-small cell lung cancer from returning. The study enrolled 448 people with stage I or II lung cancer who could not hav…

This study tested a once-monthly pill called islatravir to prevent HIV infection in cisgender men and transgender women who have sex with men and are at high risk. About 494 participants were enrolled, but the trial was terminated early. The main goal was to check safety and see …

This study tested a new monthly pill (islatravir) to see if it could prevent HIV infection better than a daily pill in 730 women at high risk. The trial was stopped early, so results are limited. The goal was to offer a more convenient prevention option.

This study tests whether adding MK-1167 to standard Alzheimer's treatment can improve memory and thinking in people with mild to moderate Alzheimer's dementia. About 350 participants will receive either MK-1167 or a placebo for 24 weeks. Researchers will measure changes in cognit…

This study tested whether MK-1942, when added to standard antidepressants, could help people with treatment-resistant depression. About 99 participants were planned, but the trial was terminated early. The goal was to measure changes in depression scores and safety.

This early-stage study tested an experimental drug called MK-6552 in 9 people with narcolepsy type 1, a condition that causes sudden sleep attacks. The goal was to see if the drug was safe and could help patients stay awake during the day. The trial was stopped early, so results …